Hereditary Angioedema (HAE) Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Intellia Therapeutics

As per DelveInsight, the Hereditary Angioedema Market is anticipated to evolve immensely in the coming years owing to the expected launch of novel emerging therapies and the rise in the number of cases of Hereditary Angioedema.

DelveInsight's "Hereditary Angioedema (HAE) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hereditary Angioedema Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Hereditary Angioedema therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hereditary Angioedema treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Hereditary Angioedema (HAE): An Overview
Hereditary Angioedema is an inherited autosomal dominant disorder conferring a 50% chance of inheritance to offspring when one of the parents is affected, although 25% of cases arise from spontaneous mutations. Identification of defects in the SERPING1 gene and several other recently identified genes has added to the understanding of the pathophysiology of Hereditary Angioedema significantly.

Hereditary Angioedema is classified into three types based on the problem it engenders. A person can have low levels of C1-INH in the body (Type I HAE), poorly functioning C1-INH (Type II HAE), or HAE with normal functioning C1-INH (formerly known as Type III HAE). The last type is extremely rare and poorly understood.

The clinical features of Hereditary Angioedema are recurrent and unpredictable spontaneous edema attacks; traumas, infections, stress, or medical procedures are potential triggers for Hereditary Angioedema attacks. Occasionally, angioedema could be associated with prodromal signs, including erythema marginatum. For diagnosis of Hereditary Angioedema, a blood test is recommended. The levels of the proteins C4 and C1 esterase inhibitors are measured to distinguish the presence of Hereditary Angioedema by type.

Hereditary Angioedema (HAE) Market Key Facts
• The total Hereditary Angioedema market size in the 7MM was estimated to be around USD 2,300 million in 2022.
• Among all the 7MM, the US consistently captured the highest Hereditary Angioedema market with nearly USD 1,900 million estimated in 2022, which is expected to grow during the forecasted period (2023-2032).
• In 2022, EU4 and the UK countries captured an estimated 16% share of the total 7MM Hereditary Angioedema market, which is estimated to rise by 2032.
• Among the 7MM, Japan represented approximately 2% of the total Hereditary Angioedema market, with USD 40 million in 2022.
• As per DelveInsight's assessment, the total diagnosed prevalent cases of Hereditary Angioedema in the 7MM in 2022 was 13,900 which is expected to increase by 2032, at a considerable CAGR.
• Among the European countries, the UK had the highest diagnosed prevalent population of Hereditary Angioedema, with nearly 1,400 cases, followed by Germany, which had 1,300 diagnosed prevalent population in 2022. On the other hand, Spain and Italy had the lowest number of diagnosed prevalent populations, each having less than 1000 cases in 2022.

Get a Detailed Overview of the Evolving Hereditary Angioedema Market Trends @
https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hereditary Angioedema (HAE) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hereditary Angioedema therapies in the market. It also provides a detailed assessment of the Hereditary Angioedema market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Hereditary Angioedema drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Hereditary Angioedema Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hereditary Angioedema (HAE) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Hereditary Angioedema patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Hereditary Angioedema (HAE) Epidemiology Segmented as -
• Total Diagnosed Prevalent Cases Of Hereditary Angioedema
• Type-specific Diagnosed Prevalent Cases of Hereditary Angioedema
• Age-specific Diagnosed Prevalent Cases of Hereditary Angioedema
• Gender-specific Diagnosed Prevalent Cases of Hereditary Angioedema

Get Key Insights Into the Evolving Hereditary Angioedema Epidemiology Trends @
https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hereditary Angioedema (HAE) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to be launched during the study period. The analysis covers the market share by Hereditary Angioedema drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Hereditary Angioedema Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Hereditary Angioedema Market @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hereditary Angioedema (HAE) Therapeutics Assessment
While there is no cure for Hereditary Angioedema, there are many ways to prevent or subdue swelling attacks. Several Hereditary Angioedema-specific agents are currently available, including attenuated androgens; while regional availability, regulatory approvals, and/or cost barriers may prevent access to some of these medications, other less proven therapies may have a role, including antifibrinolytics and fresh frozen plasma.

The market overall has been segmented into two treatment strategies commonly used for Hereditary Angioedema: on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Long-term prophylaxis of attacks reduces disease burden; short-term (or periprocedural) prophylaxis treatment is taken before activities are known to trigger attacks.

Three classes of drugs - C1-INHs, 17 alpha-alkylated androgens, and antifibrinolytics - are currently being used for long-term prophylaxis of Type I and II Hereditary Angioedema, and a monoclonal antibody, lanadelumab, was approved in the US and Europe for this indication.

Several major pharma and biotech companies are actively involved in the development of therapeutic solutions for Hereditary Angioedema. Among these, KalVista Pharmaceuticals emerges as a significant player, with its Hereditary Angioedema drug candidates progressing to the most advanced stage, Phase III of clinical trials.

Leading Companies in the Hereditary Angioedema (HAE) Therapeutics Market Include
• BioCryst Pharmaceuticals
• KalVista Pharmaceuticals
• Pharvaris
• BioMarin Pharmaceutical
• Ionis Pharmaceuticals
• Intellia Therapeutics
And Many Others

Emerging and Marketed Hereditary Angioedema (HAE) Therapies Covered in the Report Include
• Sebetralstat/KVD900: KalVista Pharmaceuticals
• NTLA-2002: Intellia Therapeutic
• PHA121: Pharvaris
• BMN 331: BioMarin Pharmaceutical
• Garadacimab (CSL312): CSL Behring
• Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals, Inc.
• STAR-0215: Astria Therapeutics, Inc.
• PHA-121: Pharvaris Netherlands B.V.
And Many More

Learn More About the Emerging Therapies and key Companies in the Hereditary Angioedema Therapeutics Market @
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hereditary Angioedema Competitive Intelligence Analysis
4. Hereditary Angioedema Market Overview at a Glance
5. Hereditary Angioedema Background and Overview
6. Hereditary Angioedema Patient Journey
7. Hereditary Angioedema Epidemiology and Patient Population
8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices
9. Hereditary Angioedema Unmet Needs
10. Key Endpoints of Hereditary Angioedema Treatment
11. Hereditary Angioedema Marketed Products
12. Hereditary Angioedema Emerging Therapies
13. Hereditary Angioedema Seven Major Market Analysis
14. Attribute Analysis
15. Hereditary Angioedema Market Outlook (7 major markets)
16. Hereditary Angioedema Access and Reimbursement Overview
17. KOL Views on the Hereditary Angioedema Market.
18. Hereditary Angioedema Market Drivers
19. Hereditary Angioedema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.